UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients

With Two Late-Stage Candidates

04 Mar 2021

• By John Davis

Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.

Grand Place, Brussels — Brussels, Where UCB is headquartered • Source: Shutterstock

Improving treatment options in generalized myasthenia gravis patients with individualized therapies is part of UCB S.A.’s vision for its two late-stage candidates – rozanolixizumab and zilucoplan – according to chief medical officer Iris Loew-Friedrich.

Treatment with a complement C5 inhibitor like zilucoplan might address the root cause of the disease for the 80% of patients with acetylcholine receptor auto-antibodies, and offer a maintenance therapy which is easy to administer via a daily subcutaneous injection, Loew-Friedrich explained during an analysts’ briefing on the company’s annual results last week

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.